Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB080 in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia
NL-OMON60089Phase 2Withdrawn
- Sponsor
- Biogen
- Start
- Mar 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of biib080 in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (4 arms), sponsored by Biogen. Primary endpoint: Dose-response in change from baseline to Week 76 on Clinical Dementia Rating-Sum of Boxes. Planned start Mar 2023; status: withdrawn.
02
Drugs
biib080
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NL-OMON60089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60089.